Welcome to our dedicated page for Inhibitor Therapeutics SEC filings (Ticker: INTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inhibitor Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inhibitor Therapeutics's regulatory disclosures and financial reporting.
Black Robe Capital LLC, a 10% owner of Inhibitor Therapeutics, Inc., together with Chief Financial Officer James A. McNulty as reporting persons, recorded a bona fide gift of 3,200,000 shares of common stock on July 1, 2026. Following this disposition, the reporting holder directly owned 19,901,057 common shares.
OSMAN RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that director and ten percent owner Ronald E. Osman received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval. After this award, reported indirect ownership totals 23,614,985 common shares, consisting of 100,000 shares held by Mr. Osman and the remaining shares held by the Ronald E. Osman Trust III, for which he serves as sole trustee.
Yanez Michelle reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Michelle Yanez received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the company’s 2025 Equity Incentive Plan, subject to shareholder approval, increasing her direct holdings to 1,221,271 common shares.
SEARS SAMUEL P JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Samuel P. Sears Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. After this award, he directly holds 1,229,543 common shares.
ODONNELL FRANCIS E JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that Chief Executive Officer Francis E. O'Donnell Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026, at $0.00 per share as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. Following this award, he directly holds a total of 150,000 common shares.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Jerman Michael Allen received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. Following this award, he directly holds 180,411 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market trade.
Vasisht Niraj reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Niraj Vasisht received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. The grant was recorded at a price of $0.00 per share, and his directly held common stock position increased to 200,000 shares following this award.
Inhibitor Therapeutics, Inc. reported a Q1 2026 net loss of $0.7 million with no revenue, reflecting its development-stage focus. Research and development expenses were $0.3 million and general and administrative expenses were $0.4 million.
Cash and cash equivalents declined to $1.29 million as of March 31, 2026, with negative operating cash flow of $1.08 million. Total assets were $1.43 million versus total liabilities of $3.41 million, resulting in a stockholders’ deficit of $2.0 million.
The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, limited cash and projected liquidity shortfalls. A planned $3.0 million registered direct financing for common stock and warrants has not funded, and the company has initiated litigation against the investor over the securities purchase agreement, adding uncertainty around future liquidity.
Inhibitor Therapeutics, Inc. furnished an update on its itraconazole program for Gorlin Syndrome, covering clinical progress, formulation strategy and intellectual property plans. The company is running a three-way crossover pharmacokinetic study in healthy adults in Malaysia under fasting conditions, in collaboration with Avior Bio.
Period 2 dosing is scheduled for April 10, 2026 and Period 3 for April 24, 2026, with plasma samples expected to be shipped for bioanalysis on or about May 1, 2026. Inhibitor believes this PK study is expected to be the final clinical study before a planned New Drug Application for surgically eligible basal cell carcinomas in BCCNS.
The program uses a proprietary amorphous itraconazole formulation intended to improve solubility and absorption versus conventional crystalline drug. Inhibitor is also preparing a new global patent application on this formulation, which it expects would be owned by the company without ongoing royalty obligations and would complement its existing oncology-focused IP portfolio.